Peanut Allergy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Peanut Allergy Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the Peanut Allergy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Peanut Allergy Pipeline Report
- DelveInsight’s Peanut Allergy Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Peanut Allergy treatment.
- The leading companies working in the Peanut Allergy Market include DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
- Promising Peanut Allergy Pipeline Therapies in the various stages of development include Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
- October 2023: ALK-Abello A/S announced a study of Phase 1 clinical trials for Peanut SLIT-tablet. This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet. This is a phase I, open-label, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 2 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents and part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children.
- Novemeber 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for ligelizumab. This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy.
Request a sample and discover the recent advances in Peanut Allergy Treatment Drugs @ Peanut Allergy Pipeline Report
In the Peanut Allergy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Peanut Allergy NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Peanut Allergy Overview
A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system —the body’s natural defense system that fights infections and diseases—overreacts and can cause a serious, even life-threatening response.
Find out more about Peanut Allergy Therapeutics Assessment @ Peanut Allergy Preclinical and Discovery Stage Products
Peanut Allergy Emerging Drugs Profile
- Viaskin Peanut: DBV Technologies
- Dupilumab: Regeneron Pharmaceuticals/Sanofi
- CNP-201: Cour Pharmaceutical
Peanut Allergy Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the Peanut Allergy therapies. The Peanut Allergy companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include, DBV Technologies.
DelveInsight’s Peanut Allergy Pipeline report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intradermal
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Peanut Allergy Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Peanut Allergy Pipeline Therapies @ Peanut Allergy Clinical Trials Assessment
Scope of the Peanut Allergy Pipeline Report
- Coverage- Global
- Peanut Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Peanut Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Peanut Allergy Companies- DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
- Peanut Allergy Pipeline Therapies- Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
Dive deep into rich insights for new drugs for Peanut Allergy Treatment, Visit @ Peanut Allergy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Peanut Allergy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Preregistration)
- Viaskin Peanut: DBV Technologies
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Dupilumab: Regeneron Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- CNP-201: Cour Pharmaceutical
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Peanut-NE01 vaccine: BlueWillow Biologics
- Drug profiles in the detailed report…..
- Inactive Products
- Peanut Allergy Key Companies
- Peanut Allergy Key Products
- Peanut Allergy- Unmet Needs
- Peanut Allergy- Market Drivers and Barriers
- Peanut Allergy- Future Perspectives and Conclusion
- Peanut Allergy Analyst Views
- Peanut Allergy Key Companies
- Appendix
For further information on the Peanut Allergy Pipeline therapeutics, reach out to Peanut Allergy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peanut-allergy-market
){kind=link}